Nemes Laszlo
- Allogene Therapeutics (ALLO) is up \~46% in Monday morning trading after releasing the results of an interim futility analysis of a pivotal phase 2 trial of the CAR-T therapy cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma.
- At the data